FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000623984> ?p ?o ?g. }

• W3000623984 abstract "To the Editor: Chronic hemolysis is a prevalent characteristic of sickle cell anemia that intensifies during times of illness, such as infection, acute chest syndrome (ACS), and vaso-occlusive pain episodes.1 Hemolysis causes the release of cell-free hemoglobin and free plasma heme2 which can damage lipid, protein, and DNA through the generation of reactive oxygen species and inflammatory signaling pathways.3 The plasma protein haptoglobin (HP) binds to and clears cell-free hemoglobin from circulation thereby preventing its deleterious effects.4, 5 A common variant in the HP gene may offer a genetic risk factor for disease-related complications in SCA. Plasma protein haptoglobin has two predominant alleles in humans (1 and 2) leading to three possible genotypes: HP1-1, HP1-2, and HP2-2. The HP2-2 protein has shown a decreased efficiency and lower affinity for binding cell-free hemoglobin; thus, the ability to scavenge cell-free hemoglobin is genotype dependent.6 The HP2-2 protein also has a lower circulating concentration and poorer protection against oxidative damage from cell-free hemoglobin in vitro.7-9 The role of HP genotype and its relation to disease severity has been studied in multiple disease states such as epilepsy,10 cardiovascular disease,11, 12 hypercholesteremia,13 diabetes,14 hemochromatosis,15 and sub-arachnoid hemorrhage,16, 17 with variable results. However, there is little data investigating the role of these genotypes in SCA. We hypothesized that children with SCA and the HP2-2 genotype will have an increased incidence of vaso-occlusive pain and ACS episodes, compared to those with the HP1-1 and HP1-2 genotypes. To test this hypothesis, we examined the impact of HP genotype on the development of pain and ACS episodes in a primary cohort of children with SCA. We then sought to validate our findings in a replication cohort of age-matched children with SCA. The primary cohort included participants enrolled in the Sleep and Asthma Cohort (SAC), a prospective cohort study of 246 children and adolescents with SCA (HbSS, HbSβ0). Children aged 4 to 18 years were enrolled and followed between 2005 and 2011 as previously described.18 A total of 199 participants from the SAC study with DNA available for genotyping were included in the primary cohort. These participants had a mean age of 10.8 years (range 4.0-19.3 years), had DNA available, laboratory data collected at baseline, and were followed for at least 1 year during the study period (mean 5.0, range 1.1-6.7 years). The replication cohort included participants enrolled in the Cooperative Study of Sickle Cell Disease (CSSCD), a multi-institutional prospective cohort study of 4085 individuals with SCA (HbSS, HbSβ0) from 23 U.S. academic hospitals, that followed participants from 1977 to 1995 in a standardized fashion.19, 20 A total of 458 participants from the CSSCD were included as they had GWAS data available, laboratory data collected at baseline, were between 4-19 years of age (mean age 11.1 years, range 4.0-19.3 years), and were followed for at least 1 year during the study period (mean 6.3, range 2-8.2 years), in order to harmonize the data with the primary (SAC) cohort. Uniform definitions for acute pain and ACS were utilized in both the SAC and CSSCD cohorts.21 An acute pain episode was defined as a hospitalization for SCA-associated pain, excluding headaches, and requiring opioid treatment. Acute chest syndrome was defined as a new clinical or radiographic pulmonary infiltrate in the context of an acute illness, characterized by respiratory symptoms with or without fever. Respiratory symptoms included cough, wheezing, rales, chest pain, decreased oxygen saturation (decrease >2% from baseline), use of accessory muscles of respiration, or increased respiratory rate. Pneumonia was included in this ACS definition. Both pain and ACS rates were calculated as events per year to account for variable follow-up duration. Table 1 shows descriptive statistics of both cohorts. The HP genotype was assessed by two methods: direct PCR and imputation, with a subset of subjects undergoing both methods in order to determine agreement between methods. For the SAC cohort, analysis of HP genotype was done by direct HP genotyping using an established real-time TaqMan PCR method.22 Next, in a subset of 187 SAC participants who had both DNA available for direct PCR genotyping and GWAS level genotyping, we validated a previously published imputation method13 in this US population of African Ancestry. Using GWAS data, HP genotype was determined based on imputation of HP structural features from surrounding SNPs.13 We observed excellent agreement between genotyping methods (Cohen's Kappa 0.84, balanced accuracy 90%, 95% CI [85%; 93%]). After this validation, imputation was used to determine HP genotype in the replication CSSCS cohort (Figure S1 and Table S1 ). The distribution of haptoglobin genotypes in both cohorts was similar to the distribution previously reported among patients with SCA23 and individuals of African ancestry.8 In the SAC cohort, 60 participants were HP1-1 (30%), 91 were HP1-2 (46%), and 48 were HP2-2 (24%). In the CSSCD cohort, 108 were HP1-1 (24%), 237 were HP1-2 (52%), and 113 were HP2-2 (25%) (Figure S2). In multivariable negative binomial regression models, HP2-2 genotype was associated with an increased rate of severe vaso-occlusive pain when compared to the HP1-1 and HP1-2 genotypes in both the SAC cohort (incidence rate ratio [IRR] 1.64, 95% confidence interval [CI] 1.04-2.58, P = .03) and the CSSCD cohort (IRR 1.57, 95% CI 1.03-2.39, P = .04) (Figure 1). Older age and increased WBC count were also associated with a modest increase in pain rate in the SAC cohort, as has been demonstrated previously.24, 25 In the CSSCD cohort, higher WBC was associated with a significantly decreased rate of pain, but with a minimal effect size (IRR 0.95, 95% CI 0.90-0.99, P = .04). In contrast, HP2-2 was not independently associated with an increased rate of ACS episodes in either cohort. Increased WBC was associated with an increased rate of ACS episodes in the SAC cohort (IRR 1.07, 1.02-1.13, P = .01) while no covariates were associated with an increased rate of ACS episodes in the CSSCD cohort (Table S2). Sickle cell anemia is a chronic hemolytic disease with a range of severity of hemolysis both over time in an individual and between individuals. Kato et al have put forth a working hypothesis that the products of intravascular hemolysis damage the vascular system and contribute to the pathophysiology of SCA.26 We have expanded on this concept to show that genetic variation in the ability to scavenge cell-free hemoglobin is also implicated in SCA-related morbidity. In children with SCA, the HP2-2 genotype is associated with a significantly increased rate of severe acute vaso-occlusive pain episodes in both our primary and replication cohorts, with an increase of 64% and 57% respectively, compared to HP1-1 and HP1-2 genotypes. This association was shown in the primary cohort by direct molecular analysis of HP genotyping and confirmed in the replication cohort by imputation of the HP2-2 genotype from GWAS data. In addition, we validated the use of HP imputation for assessment of the impact of HP variants on clinical outcomes in a US population of African ancestry, as demonstrated by the high correlation between PCR-based and imputed HP genotypes. The effect of haptoglobin genotype on morbidity and mortality has been studied in other acute and chronic diseases, with variable results. Individuals with the HP2-2 genotype have been found to have increased risk for diabetic cardiovascular and renal disease,11, 27 cognitive decline among those with type 2 diabetes,28 delayed brain injury after subarachnoid hemorrhage,16 and development of ARDS in sepsis.21 Other studies have shown no apparent association between risk for iron accumulation in hereditary hemochromatosis,15 cardiovascular risks in individuals with elevated HbA1C,12 or outcomes after subarachnoid hemorrhage.17 To our knowledge, this is the first study to examine how variations in the haptoglobin genotype may contribute to morbidity in children with SCA. Previous studies have shown that the HP2-2 protein has a decreased efficiency and lower binding affinity for cell-free hemoglobin.8 These data, taken in conjunction with the finding that heme infusion leads to endothelial damage and vaso-occlusion in transgenic SCA mice,29 highlight the importance of heme-mediated injury in the pathophysiology of SCA. Additionally, studies conducted in SCA mice demonstrate infusion of human haptoglobin prevents hemoglobin mediated vaso-occlusion and protects against heme-induced death.29 Haptoglobin infusions have been proposed as a therapeutic intervention for adults with SCA, however this intervention has yet to be explored in clinical trials.30 The current study finds an increased risk for episodes of acute severe vaso-occlusive pain among children with SCA and the HP2-2 genotype, supporting an important role for hemoglobin scavengers in modulating heme-mediated injury in SCA. Although further studies will be needed to provide insight into biological mechanisms of these processes, therapeutic strategies to decrease cell-free hemoglobin may complement other treatment strategies such as hydroxyurea, or anti-selectin antibodies. These complementary therapeutic strategies may attenuate the incidence rates of severe acute pain episodes in children with SCA. In summary, in two large cohorts of children with SCA, HP2-2 genotype was associated with an increased risk for the development of acute severe vaso-occlusive pain episodes. The HP genotype may prove to be an important predictor of morbidity in children with SCA. Further research is needed to fully understand the role of the haptoglobin genotype and the oxidative effect of cell-free hemoglobin and free plasma heme in the pathophysiology of SCA. Supported in part by the National Heart, Lung, and Blood Institute: HL R01 87681, R01 068970 and RC2 HL101212 (Steinberg), NIH 1R01HL079937 (DeBaun), NIH K24 HL103836 (Ware), NIH HL135849 (Ware and Bastarache), and NIH T32HL087738-12 (Bernard). Dr. Ware has served on advisory boards for Bayer, Merck, Quark and CSL Behring and receives research funding from CSL Behring and Genentech. S.M.W. performed genotyping in participant samples, analyzed and interpreted the data, drafted and revised the manuscript. M.R. analyzed and interpreted the data and revised the manuscript. J.B.M. assisted with genotyping and revised the manuscript. E. V. K did the imputation of haptoglobin genotypes from GWAS data and revised the manuscript. C.M.S. and J.A.B. contributed to interpretation of data and critical revision of the manuscript. M.H.S. participated in acquisition and interpretation of GWAS data and critical revision of the manuscript, M.R.D. conceived and designed the SAC study, participated in acquisition and interpretation of the data and drafting and revision of the manuscript. L.B.W. contributed to study design, interpretation of the data, and drafting and revision of the manuscript. All authors approved the final version of the manuscript for publication. Appendix S1: Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W3000623984 created "2020-01-23" @default.
• W3000623984 creator A5017239424 @default.
• W3000623984 creator A5017253129 @default.
• W3000623984 creator A5018528325 @default.
• W3000623984 creator A5019381273 @default.
• W3000623984 creator A5046756619 @default.
• W3000623984 creator A5047418153 @default.
• W3000623984 creator A5065128454 @default.
• W3000623984 creator A5066634068 @default.
• W3000623984 creator A5085584857 @default.
• W3000623984 date "2020-01-30" @default.
• W3000623984 modified "2023-10-17" @default.
• W3000623984 title "Haptoglobin genotype predicts severe acute vaso‐occlusive pain episodes in children with sickle cell anemia" @default.
• W3000623984 cites W1272191569 @default.
• W3000623984 cites W1597130939 @default.
• W3000623984 cites W1911820095 @default.
• W3000623984 cites W1926159205 @default.
• W3000623984 cites W1984887661 @default.
• W3000623984 cites W2002344020 @default.
• W3000623984 cites W2006754069 @default.
• W3000623984 cites W2006754144 @default.
• W3000623984 cites W2025723371 @default.
• W3000623984 cites W2026891878 @default.
• W3000623984 cites W2034696230 @default.
• W3000623984 cites W2041700208 @default.
• W3000623984 cites W2049537806 @default.
• W3000623984 cites W2069391846 @default.
• W3000623984 cites W2074271496 @default.
• W3000623984 cites W2083799926 @default.
• W3000623984 cites W2108928386 @default.
• W3000623984 cites W2137512897 @default.
• W3000623984 cites W2154194383 @default.
• W3000623984 cites W2277896056 @default.
• W3000623984 cites W2401034624 @default.
• W3000623984 cites W2412227310 @default.
• W3000623984 cites W2592339311 @default.
• W3000623984 cites W2598500643 @default.
• W3000623984 cites W2799856278 @default.
• W3000623984 cites W2803098705 @default.
• W3000623984 cites W2804130946 @default.
• W3000623984 cites W2899948238 @default.
• W3000623984 cites W2977363205 @default.
• W3000623984 cites W4211008300 @default.
• W3000623984 cites W2927019543 @default.
• W3000623984 doi "https://doi.org/10.1002/ajh.25728" @default.
• W3000623984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7343605" @default.
• W3000623984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31919880" @default.
• W3000623984 hasPublicationYear "2020" @default.
• W3000623984 type Work @default.
• W3000623984 sameAs 3000623984 @default.
• W3000623984 citedByCount "4" @default.
• W3000623984 countsByYear W30006239842021 @default.
• W3000623984 countsByYear W30006239842022 @default.
• W3000623984 countsByYear W30006239842023 @default.
• W3000623984 crossrefType "journal-article" @default.
• W3000623984 hasAuthorship W3000623984A5017239424 @default.
• W3000623984 hasAuthorship W3000623984A5017253129 @default.
• W3000623984 hasAuthorship W3000623984A5018528325 @default.
• W3000623984 hasAuthorship W3000623984A5019381273 @default.
• W3000623984 hasAuthorship W3000623984A5046756619 @default.
• W3000623984 hasAuthorship W3000623984A5047418153 @default.
• W3000623984 hasAuthorship W3000623984A5065128454 @default.
• W3000623984 hasAuthorship W3000623984A5066634068 @default.
• W3000623984 hasAuthorship W3000623984A5085584857 @default.
• W3000623984 hasBestOaLocation W30006239841 @default.
• W3000623984 hasConcept C104317684 @default.
• W3000623984 hasConcept C126322002 @default.
• W3000623984 hasConcept C135763542 @default.
• W3000623984 hasConcept C172680121 @default.
• W3000623984 hasConcept C187212893 @default.
• W3000623984 hasConcept C203014093 @default.
• W3000623984 hasConcept C206396517 @default.
• W3000623984 hasConcept C2776175824 @default.
• W3000623984 hasConcept C2776317666 @default.
• W3000623984 hasConcept C2778248108 @default.
• W3000623984 hasConcept C2778620579 @default.
• W3000623984 hasConcept C2779134260 @default.
• W3000623984 hasConcept C2779234561 @default.
• W3000623984 hasConcept C2779902561 @default.
• W3000623984 hasConcept C2780075939 @default.
• W3000623984 hasConcept C2780441568 @default.
• W3000623984 hasConcept C2780976302 @default.
• W3000623984 hasConcept C54355233 @default.
• W3000623984 hasConcept C71924100 @default.
• W3000623984 hasConcept C86803240 @default.
• W3000623984 hasConcept C90924648 @default.
• W3000623984 hasConceptScore W3000623984C104317684 @default.
• W3000623984 hasConceptScore W3000623984C126322002 @default.
• W3000623984 hasConceptScore W3000623984C135763542 @default.
• W3000623984 hasConceptScore W3000623984C172680121 @default.
• W3000623984 hasConceptScore W3000623984C187212893 @default.
• W3000623984 hasConceptScore W3000623984C203014093 @default.
• W3000623984 hasConceptScore W3000623984C206396517 @default.
• W3000623984 hasConceptScore W3000623984C2776175824 @default.
• W3000623984 hasConceptScore W3000623984C2776317666 @default.
• W3000623984 hasConceptScore W3000623984C2778248108 @default.
• W3000623984 hasConceptScore W3000623984C2778620579 @default.
• W3000623984 hasConceptScore W3000623984C2779134260 @default.
• W3000623984 hasConceptScore W3000623984C2779234561 @default.

• next